Oct 2026· Cancers· Vol 18· 0 citations· 31 references
Medicine
TL;DR
Flow cytometry can provide useful information beyond CAR-T-cell enumeration and may support longitudinal immune monitoring after CAR-T-cell therapy, and may support longitudinal immune monitoring after tisagenlecleucel infusion.
Abstract
Simple Summary Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for several difficult-to-treat B-cell cancers, but the immune changes that occur after treatment are not fully understood. Most monitoring focuses primarily on circulating CAR-T cell counts. In this study, we used multiparameter flow cytometry to monitor both CAR-T cells and endogenous T cells during the first month after tisagenlecleucel infusion. CAR-T cells showed changes in expansion, differentiation, and expression of immune-related markers over time, while their overall differentiation pattern was broadly similar to that of endogenous T cells. Patients who developed neurotoxicity also showed higher absolute CAR-T cell counts in an exploratory analysis. These findings suggest that flow cytometry can provide useful information beyond CAR-T-cell enumeration and may support longitudinal immune monitoring after CAR-T-cell therapy.
Background CD19-targeting chimeric antigen receptor (CAR)-T cells have demonstrated great efficacy in treating relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Despite the high objective response rate of CAR-T cell therapy, high-risk adverse event of cytokine-release syndrome occur unexpectedly. Obj...
Yi-Cong Bian, Jin-Jie Yuan, Chen-Rong Huang et al.· Frontiers in Pharmacology· 0 citations
Compared with CD19 CAR-T therapy, CD7 CAR-T therapy was characterized by reduced CD8+ CAR-T persistence, early exhaustion, and delayed immune reconstitution, correlating with increased infections and higher non-relapse mortality.
Zhi-Peng Zhou, Yi-Yang Ding, Zhuo-Jun Liu et al.· Journal of Translational Int...· 0 citations
Although chimeric antigen receptor T-cell (CAR-T) therapy has substantially improved outcomes in diffuse large B-cell lymphoma (DLBCL), disease relapse remains a major clinical challenge. Because treatment-associated immune remodeling evolves dynamically over time, complementary biomarkers capable of longitudinally mon...
Seongcheol Park, Hyeon Ji Cho, Youngho Song et al.· ACS Sensors· 0 citations
Introduction Chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for several hematological malignancies, yet patient-specific responses and toxicities remain hard to predict. Although multiple covariates and risk scores exist, their prognostic accuracy remains limited. Methods We prospectively measur...
Jonas Schadt, M. Rohnert, Paul Matthiensen et al.· Frontiers in Immunology· 0 citations
Findings suggest that NET-associated inflammatory states may be linked to peripheral immune remodeling and altered circulating T-cell functional states during CAR–γδT-cell therapy.
Ling-Song Yao, Zhi-Yu Liu, Ying Wang et al.· Genes· 0 citations
CD19 CAR-T has achieved high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, rapid generation with durable in vivo persistence remains a major challenge. CD45RA-negative T cells exhibit sustained antileukemic activity and preserved immune memory. Here, we developed a rapid p...
Xu-Ying Pei, Meng Lv, Xiao-Zheng Zhao et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
